BCLI - Brainstorm Cell Therapeutics - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

Brainstorm Cell Therapeutics's activity chart (see below) currently has 11 price targets and 23 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50% with an average time for these price targets to be met of 513.5 days.

Most recent stock forecast was given by JASON MCCARTHY from MAXIM GROUP on 23-Jul-2025. First documented stock forecast 20-Jan-2015.

Jason Kolbert Jason Mccarthy

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 30-Oct-2024

$10

1 years 2 months 18 days ago
(23-Jul-2025)

0/4 (0%)

$8.07 (418.13%)

Hold Since 25-May-2022

$180

4 years 4 months 16 days ago
(25-May-2022)

7/7 (100%)

$134.85 (298.67%)

1027

Show more analysts

What is BCLI (Brainstorm Cell Therapeutics) average time for price targets to be met?

On average it took 514 days for the stock forecasts to be reached, with an average price target met ratio of 50%.

Which analyst most recently updated their price target on BCLI (Brainstorm Cell Therapeutics)?

Jason Mccarthy

Which analyst has the current lower performing score on BCLI (Brainstorm Cell Therapeutics) with a proven track record?

JASON MCCARTHY

Which analyst has the most public recommendations on BCLI (Brainstorm Cell Therapeutics)?

Jason Mccarthy works at MAXIM GROUP and has 4 price targets and 2 ratings on BCLI

Which analyst is the currently most bullish on BCLI (Brainstorm Cell Therapeutics)?

Jason Mccarthy with the highest potential upside of $0

Which analyst is the currently most reserved on BCLI (Brainstorm Cell Therapeutics)?

Jason Kolbert with the lowest potential downside of -$0